Document Detail

Lysophosphatidic acid in atherosclerotic diseases.
MedLine Citation:
PMID:  22568609     Owner:  NLM     Status:  MEDLINE    
Lysophosphatidic acid (LPA) is a potent bioactive phospholipid. As many other biological active lipids, LPA is an autacoid: it is formed locally on demand, and it acts locally near its site of synthesis. LPA has a plethora of biological activities on blood cells (platelets, monocytes) and cells of the vessel wall (endothelial cells, smooth muscle cells, macrophages) that are all key players in atherosclerotic and atherothrombotic processes. The specific cellular actions of LPA are determined by its multifaceted molecular structures, the expression of multiple G-protein coupled LPA receptors at the cell surface and their diverse coupling to intracellular signalling pathways. Numerous studies have now shown that LPA has thrombogenic and atherogenic actions. Here, we aim to provide a comprehensive, yet concise, thoughtful and critical review of this exciting research area and to pinpoint potential pharmacological targets for inhibiting thrombogenic and atherogenic activities of LPA. We hope that the review will serve to accelerate knowledge of basic and clinical science, and to foster drug development in the field of LPA and atherosclerotic/atherothrombotic diseases.
Andreas Schober; Wolfgang Siess
Related Documents :
8893239 - Congenital melanoma: a case suggesting rhabdomyogenic differentiation.
3788569 - Light and electron microscopic study of mucoepidermoid tumor of clear cell type.
21283119 - Proclaiming fate in the early mouse embryo.
21076079 - Generation of functional oocytes and spermatids from fetal primordial germ cells after ...
21241189 - Differentiation of embryonic stem cells using pancreatic bud-conditioned medium gives r...
19946729 - Cgmp-phosphodiesterase 6, transducin and wnt5a/frizzled-2-signaling control cgmp and ca...
23665209 - Can cell mortality determine division of labor in tissue organization?
468279 - Lack of enhanced purine biosynthesis in hgprt- and lesch-nyhan cells.
14535829 - Inhibitory effects of bcl-2 on mitochondrial respiration.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  British journal of pharmacology     Volume:  167     ISSN:  1476-5381     ISO Abbreviation:  Br. J. Pharmacol.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-09-05     Completed Date:  2013-01-17     Revised Date:  2013-10-11    
Medline Journal Info:
Nlm Unique ID:  7502536     Medline TA:  Br J Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  465-82     Citation Subset:  IM    
Copyright Information:
© 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.
Institute for Molecular Cardiovascular Research, RWTH Aachen University, Aachen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Atherosclerosis / drug therapy,  physiopathology*
Drug Design
Lysophospholipids / metabolism*
Signal Transduction
Thrombosis / drug therapy,  etiology,  physiopathology*
Reg. No./Substance:
0/Lysophospholipids; 22002-87-5/lysophosphatidic acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Anthropometry, strength and benchmarks for development: A basis for junior rowers' selection?
Next Document:  Characterizing Bioaerosol Risk from Environmental Sampling.